BioCentury
ARTICLE | Clinical News

Anti-NKG2D: Phase IIa started

November 8, 2010 8:00 AM UTC

In August, Novo Nordisk began the double-blind, placebo-controlled, German Phase IIa Study NN8555-3796 trial to evaluate 4 mg/kg subcutaneous anti-NKG2D in 54 patients. In 2008, Novo Nordisk gained ri...